Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


News In Brief

This article was originally published in The Gray Sheet

Executive Summary

DaVita buys HealthCare Partners. Boston Scientific/Philips imaging collaboration. More news briefs.

You may also be interested in...

People Briefs: Appointments At Covidien, Stryker, DaVita, InspireMD, JDRF

Covidien expands group president Bryan Hanson’s portfolio to include all business units. Stryker adds board chairmen role for CEO Kevin Lobo. More people news.

Waiting For Exhale: Emphysema Researchers Call For New Stent Designs, More Analysis

New stent designs and placement techniques are needed to develop an interventional device that successfully treats severe emphysema, researchers said following publication of disappointing study results for a drug-eluting stent system intended to create airway passages in the lung.

Cambridge Vision Achieved, AstraZeneca Looks To Realize ‘Pipeline 2’ Ambitions

Having achieved a turnaround in its R&D and commercial fortunes, AstraZeneca’s hopes the opening of a new research center will herald its next wave of novel therapies.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts